Amneal Pharmaceuticals

Amneal Pharmaceuticals received FDA tentative approval for beclomethasone dipropionate HFA inhalation aerosol, a generic version of Teva's QVAR asthma treatment.

Amneal Pharmaceuticals has commercially launched Brekiya, the first and only self-administered dihydroergotamine autoinjector approved for acute treatment of migraine and cluster headaches in adults.

Amneal Pharmaceuticals has submitted a Biologics License Application to the FDA for a biosimilar to XOLAIR (omalizumab), developed in partnership with Kashiv BioSciences.

Apiject Systems has submitted a New Drug Application to the FDA for the world's first injectable medicine using its single-dose, single-use prefilled plastic syringe containing glycopyrrolate.

Amneal Pharmaceuticals received FDA approval for its generic version of bimatoprost ophthalmic solution 0.01%, a prostaglandin analog used to reduce elevated intraocular pressure in glaucoma patients.

Amneal Pharmaceuticals received FDA approval for its generic sodium oxybate oral solution 500 mg/mL, referencing Jazz Pharmaceuticals' Xyrem for narcolepsy treatment.

The FDA issued a warning to Amneal Pharmaceuticals after discovering the company used contaminated intravenous bags in sterile injectable drug production.

Knight Therapeutics has filed a New Drug Submission for CREXONT, a novel extended-release carbidopa/levodopa formulation for Parkinson's disease, which has been accepted for review by Health Canada.

Amneal Pharmaceuticals received FDA approval for prednisolone acetate ophthalmic suspension 1%, a generic version of Allergan's Pred Forte for treating steroid-responsive ocular inflammation.

Amneal Pharmaceuticals reported Q1 2025 revenue of $695 million, a 5% year-over-year increase, with growth across all three business segments despite falling short of analyst expectations.